FDA Votes 6-0 To Back EISAI's, Biogen's Leqembi; Full Approval Would Trigger Broad Coverage Of Leqembi
Portfolio Pulse from Benzinga Newsdesk
The FDA has voted 6-0 in favor of Eisai and Biogen's Leqembi, a potential Alzheimer's treatment. Full approval would trigger broad coverage of Leqembi.
June 09, 2023 | 7:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's Leqembi, developed in partnership with Eisai, receives a 6-0 FDA vote in favor. Full approval would trigger broad coverage.
The FDA's unanimous vote in favor of Biogen's Leqembi, developed in partnership with Eisai, is a strong positive signal for the company. Full approval would lead to broad coverage of the drug, potentially increasing revenues and boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Eisai's Leqembi, developed in partnership with Biogen, receives a 6-0 FDA vote in favor. Full approval would trigger broad coverage.
The FDA's unanimous vote in favor of Eisai's Leqembi, developed in partnership with Biogen, is a strong positive signal for the company. Full approval would lead to broad coverage of the drug, potentially increasing revenues and boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80